Dramatic changes in muscle contractile and structural properties after 2 botulinum toxin injections

ABSTRACT Introduction: Botulinum toxin is frequently administered serially to maintain therapeutic muscle paralysis, but the effect of repeated doses on muscle function are largely unknown. This study characterized the muscle response to 2 onabotulinum toxin (BoNT) injections separated by 3 months....

Full description

Saved in:
Bibliographic Details
Published inMuscle & nerve Vol. 52; no. 4; pp. 649 - 657
Main Authors Minamoto, Viviane B., Suzuki, Kentaro P., Bremner, Shannon N., Lieber, Richard L., Ward, Samuel R.
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.10.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:ABSTRACT Introduction: Botulinum toxin is frequently administered serially to maintain therapeutic muscle paralysis, but the effect of repeated doses on muscle function are largely unknown. This study characterized the muscle response to 2 onabotulinum toxin (BoNT) injections separated by 3 months. Methods: Animal subjects received a single toxin injection (n = 8), 2 BoNT injections separated by 3 months (n = 14), or 1 BoNT and 1 saline injection separated by 3 months (n = 8). Results: The functional effect of 2 serial injections was exponentially greater than the effect of a single injection. While both groups treated with a single BoNT injection had decreased torque in the injected leg by approximately 50% relative to contralateral legs, the double BoNT injected group had decreased torque by over 95% relative to the preinjection level. Both single and double BoNT injections produced clear signs of fiber‐type grouping. Conclusions: These experiments demonstrate a disproportionately greater effect of repeated BoNT injections. Muscle Nerve 52: 649–657, 2015
Bibliography:Allergan, Inc.
ArticleID:MUS24576
istex:242842B8D85F39BE4736C37355D2D007E2A4B30A
Department of Veterans AffairsNIH - No. RX000670; No. R24HD050837; No. AR057013
ark:/67375/WNG-QVJ006RZ-F
Funding for this study was provided by the Department of Veterans Affairs (grant RX000670), NIH (grants R24HD050837 and AR057013), and Allergan, Inc.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0148-639X
1097-4598
1097-4598
DOI:10.1002/mus.24576